-
The Development of Novel Probes for Imaging Glucocerebrosidase Activity in Parkinson’s Disease
… glucocerebrosidase (GBA), a protein that strips sugars from molecules in the membranes of brain cells, are … to boost GBA, and identify people with PD who would benefit from GBA-enhancing drugs. Hypothesis: Our hypothesis is that …
-
Efficacy of PRKN Gene Delivery toward Mitigation of Alpha-synuclein-induced Degeneration
… aggregation and loss of dopamine-producing cells. The data from these studies may impact therapeutic approaches for … therapeutic strategy for humans. Additionally, readouts from the tools and assays we use in this project may be …
-
Proof of Concept and Translational Validation of USP30 to Offset Dysfunction in the PRKN Pathway
… study will investigate whether USP30 inhibitors can protect from degeneration of dopamine-containing cells in a … believe that people with PD and PRKN mutations may benefit from USP30 inhibitor treatment. Furthermore, repeating human …
-
Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease
June 15, 2020
… immunoassay in all available CSF samples from longitudinally studied patients with PD (n = 416) and … 3-year period, suggest biomarker profiles in PD may deviate from healthy aging. ANN NEUROL 2020;88:574-587. …
-
Sensitive ELISA-based detection method for the mitophagy marker p-S65-Ub in human cells, autopsy brain, and blood samples
September 4, 2020
… mitophagy levels in unstressed human cells and in brains from wild-type and prkn knockout mice as well as elevated p-S65-Ub levels in autopsied frontal cortex from AD patients vs. control cases. Moreover, the assay …
-
Development of Compounds that Destroy Alpha-Synuclein Aggregates for the Treatment of Parkinson’s Disease
… compounds that can clear toxic alpha-synuclein aggregates from the brain — molecules that could be developed into a … alpha-synuclein aggregates. The most promising compounds from the project will be further tested for their safety and …